Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.

ABSTRACT:

Background

Convalescent plasma, widely utilized in viral infections that induce neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might have beneficial effect. Our objective was to determine the risk factors for 28-days mortality in patients who received convalescent plasma for COVID-19 compared to those who did not, who were admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic.

Methods

This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1, 2020, including unselected, consecutive adult patients with diagnosed COVID-19, admitted to 215 hospitals with pneumonia. Epidemiological and clinical variables were registered in the Provincial Hospital Bed Management System. C

SUBMITTER: Salazar MR 

PROVIDER: S-EPMC8084206 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature